Regemat 3D to Distribute VitroInk® Bioinks: A Strategic Distribution for Advanced Bioprinting Solutions in Europe

MONMOUTH, N.J., Feb. 20, 2025 /PRNewswire/ -- TheWell Bioscience, a leading biotech company specializing in xeno-free biofunctional hydrogels and bioinks, is pleased to announce the non-exclusive distribution of its products through REGEMAT 3D, a leading biotech company specializing in the development of custom biofabrication systems, to distribute VitroINK®, a groundbreaking bioink in the field of 3D bioprinting.

REGEMAT 3D has been at the forefront of 3D biofabrication technology, providing innovative, customizable bioprinters, bioreactors, and biomaterials for tissue engineering and regenerative medicine. The distribution of TheWell Bioscience's bioinks will further enhance Regemat 3D's product portfolio and offer comprehensive solutions to researchers and clinicians worldwide.

VitroINK® is a novel xeno-free biofunctional bioink system that allows cells to be mixed directly with bioink and can bioprint without the need for UV (Ultra Violet), heat curing, or any crosslinking agents. These unique properties provide an optimal environment for cell growth and differentiation, making it an ideal solution for various applications in tissue engineering and regenerative medicine.

The distribution of VitroINK® aligns perfectly with Regemat 3D's mission to provide state-of-the-art bioprinting solutions. Regemat 3D has grown to become one of the top 15 3D bioprinting emerging companies worldwide, with a presence in more than 30 countries and collaborators in over 100 research groups. By integrating VitroINK® into its product line, Regemat 3D can offer more versatile biomaterials for its customers' research.

"Regemat 3D is committed to advancing the field of bioprinting through innovative technologies," said Manuel Figueruela, CEO at Regemat 3D. "Our partnership with TheWell Bioscience will allow us to provide our customers with cutting-edge bioinks, like VitroINK®, that can significantly enhance their research and clinical applications."

"We are thrilled to partner with Regemat 3D, a company that shares our vision for advancing the field of bioprinting. We believe that our VitroINK® bioinks, combined with Regemat 3D's advanced bioprinters, will give researchers the tools they need to make significant strides in tissue engineering and regenerative medicine," said John Huang, CEO at TheWell Bioscience.

About REGEMAT 3D

REGEMAT 3D is a researcher-founded company advancing biofabrication technologies to improve quality of life. Pioneering personalized 3D bioprinting, we hold a patent for a one-of-a-kind bioreactor capable of regenerating osteochondral knee lesions and producing functional cartilage tissue.

Offering a wide range of biomaterials and consumables, our mission is to bring biofabrication to clinical practice, enabling personalized medical therapies that shape the future of healthcare.  Discover more at: www.regemat3d.com

About TheWell Bioscience

TheWell Bioscience – developer of VitroGel®, an animal-free synthetic biofunctional hydrogel, enables scientists to shift from 2D to 3D cell culture and help drive innovations for precision medicine, cell therapy, and biomanufacturing by getting faster and more accurate data than animal-based ECMs.

Explore an array of high-throughput automation-capable hydrogels and bioinks that can open the door to 3D cell models for preclinical and clinical applications and how VitroGel® can help researchers improve personalized medicine globally.

Learn more at: www.thewellbio.com

Media Contact:
Kyra Baricaua
9738554955
[email protected]

SOURCE TheWell Bioscience